[1]Diaz LA，Bardelli A.Liquid biopsies：Genotyping circulating tumor DNA［J］.J Clin Oncol，2014，32(6)：579-586.
[2]Singh AP，Li S，Cheng H.Circulating DNA in EGFR-mutated lung cancer［J］.Ann Transl Med，2017，5(18)：379-389.
[3]Sacher AG，Paweletz C，Dahlberg SE，et al．Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAs mutations in advanced lung cancer［J］．JAMA 0ncol，2016，2(8)：1014-1022．
[4]Newman AM，Lovejoy AF，Klass DM，et al．Incegrated digital error suppression for improved detection of circulating tumor DNA［J］．Nat Biotechnol，2016，20(5)：548-554．
[5]Heitzer E，Ulz P，Geid JB．circulating tumor DNA as a liquid biopsy for cancer［J］．Clin Chem，2015，61(1)：112-123．
[6]Luo JL，Li K，Feng X，et al.Clinical utility of plasma WIF-1 gene promoter methylation detection in the early diagnosis of lung cancer［J］.J Minimally Invasive Medicine，2017，12（2)：175-178.［骆江龙，李鲲，冯旭，等.血浆WIF-1基因启动子甲基化检测在肺癌早期诊断中的临床意义［J］.微创医学，2017，12(2)：175-178.］
[7]Carpagnano GE，Foschino-Barbaro MP，Spanevello A，et al．3p microsatellite signature in exhaled breath condensate and tumor tissue of patients with lung cancer［J］．Am J Respir Crit Care Med，2008，177(3)：337-341．
[8]Chen KZ，Feng L，Fan Y，et al.Circulating tumor DNA detection in early-stage non-small cell lung cancer patients by targeted sequencing［J］.Sci Rep，2016，6：31985.
[9]Meng XW，Carbone DP.Blood-based biomarkers in lung cancer：Prognosis and treatment decisions［J］.Transl Lung Cancer Res，2017，6(6)：708-712.
[10]Abbosh C，Birkbak NJ，Wilson GA，et al.Phylogenetic ctDNA analysis depicts early stage lung cancer evolution［J］.Nature，2017，545(7655)：446-451.
[11]Paweletz CP，Sacher AG，Raymond CK，et al.Bias-corrected targeted next-generation sequencing for rapid，multiplexed detection of actionable alterations in cell-free DNA from advanced lung cancer patients［J］.Clin Cancer Res，2016，22(4)：915-922.
[12]Yu Y，Liu J，Li L，et al.Detection of circulating tumor DNA in patients with advanced non-small cell lung cancer［J］.Oncotarget，2016，8(2)：2130-2140.
[13]Mao XW，Zhang YJ，Xie FF，et al.Can peripheral blood be used as surrogate in detecting epidermal growth factor receptor mutation status in advanced non-small cell lung cancer patients? A Meta-analysis［J］.Oncotarget，2017，8(44)：78057-78067.
[14]Guo ZW，Li M，Li JQ，et al.Circulating tumor DNA detection in advanced non-small cell lung cancer patients［J］.Transl Cancer Res，2017，6(5)：878-885.
[15]Wang Y，Tian PW，Wang WY，et al.Noninvasive genotyping and monitoring of anaplastic lymphoma kinase（ALK) rearranged non-small cell lung cancer by capture-based next-generation sequencing［J］.Oncotarget，2016，7(40)：65208-65217.
[16]Cui S，Zhang W，Xiong L，et al.Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer［J］.Oncotarget，2016，8(2)：2771-2780.
[17]Liu LP，Liu H，Shao D，et al.Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in non-small cell lung cancer［J］.Genes Chromosomes Cancer，2018，57(4)：211-220.
[18]Zheng D，Ye X，Zhang MZ，et al.Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance［J］.Sci Rep，2016，6：20913.
[19]Wakelee HA，Gadgeel SM，Goldman JW，et al.Epidermal growth factor receptor（EGFR) genotyping of matched urine，plasma and tumor tissue from non-small cell lung cancer（NSCLC) patients（pts) treated with rociletinib［J］.J Clin Oncol，2016，34(15 suppl)：9001.
[20]Oxnard GR，Thress KS，Alden RS，et al.Association between plasma genotyping and outcomes of treatment with osimertinib（AZD9291) in advanced non-small-cell lung cancer［J］.J Clin Oncol，2016，34(28)：3375-3382.
[21]Ogawara D，Soda H，Suyama T，et al.Pitfalls in diagnosis with the use of circulating tumor-derived epidermal growth factor receptor mutations in lung cancer harboring pretreatment T790M［J］.Thoracic Cancer，2018，9(1)：171-174.
[22]Mok TS，Wu YL，Ahn MJ，et al.Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer［J］.N Engl J Med，2017，376(7)：629-640.
[23]Mamdani H，Ahmed S，Armstrong S，et al.Blood-based tumor biomarkers in lung cancer for detection and treatment［J］.Transl Lung Cancer Res，2017，6(6)：648-660.
[24]Volckmar A L，Sültmann H，Riediger A，et al.A field guide for cancer diagnostics using cell-free DNA：From principles to practice and clinical applications［J］.Genes Chromosomes Cancer，2018，57(3)：123-139.
[25]Yun LJ，Xu Q，Wei X，et al.Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs：Korean lung cancer consortium（KLCC-12-02)［J］.Oncotarget，2016，7(6)：6984-6993.
[26]Mok T，Wu YL，Lee JS，et al.Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy［J］.Clin Cancer Res，2015，21(14)：3196-3203.
[27]Provencio M，Torrente M，Calvo V，et al.Prognostic value of quantitative ctDNA levels in non small cell lung cancer patients［J］.Oncotarget，2018，9(1)：488-494.
[28]Cargnin S，Canonico PL，Genazzani AA，et al.Quantitative analysis of circulating cell-free DNA for correlation with lung cancer survival：A systematic review and Meta-analysis［J］.J Thorac Oncol，2017，12(1)：43-53.
[29]Li BT，Stephens D，Chaft JE，et al.Liquid biopsy for ctDNA to revolutionize the care of patients with early stage lung cancers［J］.Ann Transl Med 2017，5(23)：479-482.
[30]Carbone DP，Reck M，Paz-Ares L，et al.First-line nivolumab in stage Ⅳ or recurrent non-small-cell lung cancer［J］.N Engl J Med，2017，376(25)：2415-2426.
[31]Iijima Y，Hirotsu Y，Amemiya K，et al.Very early response of circulating tumour-derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non-small cell lung cancer［J］.Eur J Cancer，2017，86：349-357.
[32]Merriott DJ，Chaudhuri AA，Jin M，et al.Circulating tumor DNA quantitation for early response assessment of immune checkpoint inhibitors for lung cancer［J］.International Journal of Radiation Oncology Biology Physics，2017，99(2 Suppl)：S20-21.
[33]Cabel L，Riva F，Servois V，et al.Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy：A proof-of-concept study［J］.Ann Oncology，2017，28(8)：1996-2001.
[34]Cai WJ，Zhou CC，Su CX，et al.The predictive value of mutation/neoantigen burden from ctDNA on the efficacy of PD-1 blockade in advanced NSCLC［J］.J Thorac Oncol，2017，12(1 suppl)：S429-S430.
[35]Khagi Y，Goodman AM，Daniels GA，et al.Hypermutated circulating tumor DNA：Correlation with response to checkpoint inhibitor-based immunotherapy［J］.Clin Cancer Res，2017，23(19)：5729-5736.
[36]Gandara DR，Kowanetz M，Mok TSK，et al.Blood-based biomarkers for cancer immunotherapy：Tumor mutational burden in blood（bTMB) is associated with improved atezolizumab（atezo)efficacy in 2L+NSCLC（POPLAR and OAK)［J］.Ann Oncol，2017，28(5 suppl)：v460-v496.